RSS

Parkinson's

A €7 million project at the Royal College of Surgeons in Ireland (RCSI) is hoping to deepen our understanding of Parkinson’s so that more effective treatments can be developed. Read more

News

It is now possible to accurately predict how one subpopulation of cells can be converted into another thanks to a new computational method, according to Luxembourg researchers. Read more

News

The first European approval for a Phase II clinical trial with THN102 in Parkinson’s patients has been announced by biopharmaceutical company, Theranexus. Read more

News

Lundbeck has signed a definitive agreement to acquire biopharma company, Prexton Therapeutics, obtaining the global rights for foliglurax — a treatment for Parkinson’s that has recently entered clinical Phase II testing. Read more

News

An exclusive licence agreement has been announced for the importation, packaging and commercialisation of Opicapone — a new treatment for Parkinson’s disease — in China (excluding Hong Kong, Macao and Taiwan). Read more

News

Gene control company, Synpromics, has revealed its collaboration with University College London (UCL) for the generation of a range of synthetic gene promotors for the central nervous system (CNS) to develop a therapy for Parkinson’s disease. Read more

News

First patient has been implanted with a novel drug delivery system, developed by Renishaw, for a new clinical study investigating it as a delivery method for cerebral dopamine neurotrophic factor (CDNF) as a treatment for Parkinson’s disease. Read more

Technology

Gene editing and gene modulation technologies company, Horizon Discovery, has announced a partnership with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to introduce two new pre-clinical models. Read more

News

Titan Pharmaceuticals has announced that the first patient has been treated in a Phase I/II trial of its ropinirole subdermal implant for the treatment of the signs and symptoms of idiopathic Parkinson’s disease. Read more

News

A collaboration has been announced between AstraZeneca and Takeda Pharmaceutical Company for the development and commercialisation of an alpha-synuclein antibody, MEDI1341, as a potential treatment for Parkinson’s disease. Read more

News

A new study, led by University College London, has demonstrated that a diabetes drug (exenatide) may offer potentially disease-modifying attributes to patients suffering from Parkinson’s disease. Read more

News

The US FDA has approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s currently being administered levodopa/carbidopa and experiencing ‘off’ periods. Read more

News

According to business intelligence provider GBI Research, pharmaceuticals company Roche will be the biggest mover in the neurodegenerative drugs space over the next five years. Read more

News

Scientific technology company Renishaw is being supported by the Horizon 2020 programme for its trials of a new drug delivery system aiming to help treat Parkinson’s disease. Read more

News

Biopharmaceutical company PhoreMost has entered into a research collaboration with the laboratory of Professor David Rubinsztein at the University of Cambridge. Read more

News

Pharmaceutical firm UCB Manufacturing Ireland have gained massive profits, chiefly arisen from the sale of the IP of its Parkinson’s disease drug. Read more

News

Innovation – it’s everywhere in the pharmaceutical sector. Sometimes it’s a small step but more often it's continued effort into drug development, delivery or research that leads to the constant stream of new products and formulations Read more

News

Pfizer, AstraZeneca, Merck and other Big Pharma companies have signed up to a consortium aimed at accelerating the development of safe and effective therapies for Parkinson’s Read more

News

Cynapsus Therapeutics and The Michael J. Fox Foundation for Parkinson's Research (MJFF) are working together to incorporate wearable device technology and "big data" approaches to a Parkinson’s clinical trial Read more

News

Following hot on the heels of yesterday’s announcement that Eli-Lilly’s drug solanezumab heralded a breakthrough in the treatment of Alzheimer’s, the EPM team has done some digging and presents four additional newsworthy developments in the field. Read more

News